PODCAST

Gastroenterology and Hepatology

ReachMD

science & medicine medicine

All Episodes

00:00:00

Chairperson's Perspective: Innovative Approaches to...

Gastroenterology and Hepatology ·

2025/06/09

Host: Darren Brenner, MD Irritable bowel syndrome with constipation (IBS-C) significantly impacts patients, not only with its physical symptoms of persistent constipation, abdominal pain, and bloating, but also through a considerable psychological and social burden. Do you know how to effectively treat IBS-C to increase your patients’ quality of life? Tune in for an overview of the latest data.

00:00:00

Acute Kidney Injury in Cirrhosis: Multidisciplinary...

Gastroenterology and Hepatology ·

2025/01/24

Host: Nancy S. Reau, MD Guest: Andrew Allegretti, MD, MSc Guest: Kevin Regner, MD Guest: Ram Subramanian, MD In patients with decompensated cirrhosis and multi-organ failure, intensive care units must coordinate care between hepatologists, transplant surgeons, intensivists, and nephrologists to optimize patient outcomes. This roundtable highlights the importance of well-coordinated processes between floor units and ICU teams, including early response systems and regular

00:00:00

Preparing the Patient with Decompensated Cirrhosis...

Gastroenterology and Hepatology ·

2025/01/24

Host: Brian P. McDonough, MD, FAAFP Guest: Andrew Allegretti, MD, MSc Guest: Ram Subramanian, MD In patients with cirrhosis and kidney dysfunction who are candidates for liver transplantation, transplant decisions are impacted by kidney function impacting MELD scores. This podcast explores ICU management of these patients, including the use of dialysis, and emphasizes the importance of considering multiple factors such as the etiology of liver disease, presence of chronic

00:00:00

Evaluation and Management of AKI in Cirrhosis: At the...

Gastroenterology and Hepatology ·

2025/01/17

Host: Brian P. McDonough, MD, FAAFP Guest: Nancy S. Reau, MD Guest: Kevin Regner, MD In patients with advanced liver disease, decompensated cirrhosis and portal hypertension can impact kidney function through development of acute kidney injury (AKI). Multiple different etiologies of AKI can be seen in cirrhotic patients, including prerenal AKI, acute tubular injury, and hepatorenal syndrome (HRS), which require different treatment approaches. This podcast will emphasize the

00:00:00

The Importance of PD-L1 Testing: Shaping the Future...

Gastroenterology and Hepatology ·

2024/12/20

Host: Harry Yoon, MD This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection

00:00:00

Distinguishing Between Anti-PD-1 Agents in ESCC...

Gastroenterology and Hepatology ·

2024/12/20

Host: Jaffer Ajani, MD This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection

00:00:00

Effective Monitoring and Management of Adverse...

Gastroenterology and Hepatology ·

2024/12/20

Host: Harry Yoon, MD Guest: Jaffer Ajani, MD This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform

00:00:00

The Changing Paradigm of Treating MASLD/MASH: At the...

Gastroenterology and Hepatology ·

2024/12/17

Host: Naim Alkhouri, MD, FAASLD, DABOM MASLD/MASH is a serious, chronic, progressive disease that will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. Do you know how to effectively treat MASLD/MASH in your patients, and are you familiar with drugs currently in development? Tune in for an overview of the latest data.

00:00:00

Does Your Patient Have PBC?

Gastroenterology and Hepatology ·

2024/11/08

Guest: Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus

00:00:00

Advances in the Treatment of PBC: Part 2

Gastroenterology and Hepatology ·

2024/11/08

00:00:00

Advances in the Treatment of PBC: Part 1

Gastroenterology and Hepatology ·

2024/11/08

Host: Gideon Hirschfield, MB, BChir, PhD Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to

00:00:00

Don't Forget, There's an Itchy Patient Behind Those...

Gastroenterology and Hepatology ·

2024/11/08

Guest: Elizabeth K. Goacher, PA-C Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor

00:00:00

PBC Is Risky Business

Gastroenterology and Hepatology ·

2024/11/08

00:00:00

Don't Forget, There's a Sleepy Patient Behind Those...

Gastroenterology and Hepatology ·

2024/11/08

00:00:00

Initiating Second-Line Therapy: What, When, and Then...

Gastroenterology and Hepatology ·

2024/11/08

00:00:00

PBC Target Practice: Normalization Is the New Norm

Gastroenterology and Hepatology ·

2024/11/08

16 results

Gastroenterology and Hepatology

All Episodes

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事